Brain MRI study to confirm a marker in ALD
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study checks whether a brain MRI scan can confirm a blood/planning marker that predicts how X-linked adrenoleukodystrophy (ALD) may progress. If you have ALD, it may help researchers better track the condition using safer, non-invasive imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- Patients must be male and have a confirmed ALD gene change (ABCD1 pathogenic variant)
- You (or the study team) must be able to do an MRI (no safety issues and you can lie still in the scanner)
- You must not have other major brain problems like brain tumor, stroke, or a significant head injury
- You cannot be in another interventional clinical trial at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information and test results from people with X-linked adrenoleukodystrophy (X-ALD) and some genetic carriers. It helps researchers better understand the condition and how it varies, which can guide future care and studies.
This study follows women with a genetic condition called X-linked adrenoleukodystrophy (ALD) over time to see how the disease progresses. It includes annual check-ups and MRI scans of the brain and spinal cord to monitor changes.
This study looks at quality of life in adult women who have X-linked adrenoleukodystrophy (X-ALD). It may help researchers understand how this condition affects daily life and well-being.
This study collects brain-related medical information and biological samples to help researchers better understand leukodystrophies and other white-matter brain disorders. It may help future diagnosis and treatments by building a valuable “biobank” of patient data and samples.
This trial studies an experimental gene therapy given through infusion (IV) and into the spinal fluid (injection) for people with X-ALD affecting the brain. It aims to improve or slow down damage in the nervous system, and you must be able to do MRI scans and meet specific health and infection requirements.
This study looks at immune cells in blood to better understand rare brain conditions caused by genetic changes. It may help researchers understand why symptoms happen and how the immune system is involved.
Hear when a new X-linked Adrenoleukodystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.